Genetic Manipulation of Tumor-specific Cytotoxic T Lymphocytes to Restore Responsiveness to IL-7
Open Access
- 1 May 2009
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 17 (5), 880-888
- https://doi.org/10.1038/mt.2009.34
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patientsJCI Insight, 2008
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1JCI Insight, 2008
- Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsetsThe Journal of Experimental Medicine, 2008
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Effects of IL-7 on memory CD8+ T cell homeostasis are influenced by the timing of therapy in miceJCI Insight, 2008
- Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytesBlood, 2007
- Epstein Barr virus–specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin diseaseBlood, 2007
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- IL-7 Administration to Humans Leads to Expansion of CD8+ and CD4+ Cells but a Relative Decrease of CD4+ T-Regulatory CellsJournal of Immunotherapy, 2006